Last patient being randomized in oral prolonged-release ketamine trial for Treatment-Resistant Depression!

28.03.2023 Develco Pharma and HMNC Brain Health announce last patient being randomized in oral prolonged-release ketamine trial for Treatment-Resistant Depression! An increasing number of people suffer from depression. It is very important to help and support these people. We are proud to announce that Develco, together with HMNC Brain Health, randomized the last patient in its proof-of-concept Phase II clinical trial of ‘Ketabon’ (KET01), an oral prolonged-release ketamine formulation for Treatment-Resistant Depression. „The goal with KET01 is to improve the lives of patients who are not responding to standard antidepressant therapies, as well as to provide a well-tolerated antidepressant with substantially limited dissociative side effects,” said Dr. Hans Eriksson, Chief Medical Officer at HMNC Brain Health. For more detailed information, please have a look at the media release of Ketabon by clicking on the following link: https://lnkd.in/e2AsJc9n #DevelcoPharma #HMNCBrainHealth #ketabon #TreatmentResistantDepression #trd #DepressionTherapy #depression #pharma

The release as fetched from its publisher. develco.ch ↗